These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 27168431)
1. Drug Regulation and Pricing--Can Regulators Influence Affordability? Eichler HG; Hurts H; Broich K; Rasi G N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431 [No Abstract] [Full Text] [Related]
2. The ongoing regulation of generic drugs. Frank RG N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956 [No Abstract] [Full Text] [Related]
3. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs. Feldman R; Wang C N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550 [No Abstract] [Full Text] [Related]
4. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance. Zhao M; Wu J Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144 [TBL] [Abstract][Full Text] [Related]
5. Precompetitive research: a new prescription for drug development? Woodcock J Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454 [No Abstract] [Full Text] [Related]
6. An ethical dilemma. Patents & profits v. access & affordability. Blasi AE J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710 [No Abstract] [Full Text] [Related]
7. Pharmaceutical R&D: an age of change? Baldwin JJ Future Med Chem; 2014 Jun; 6(10):1109-12. PubMed ID: 25078132 [No Abstract] [Full Text] [Related]
8. An uncertain future for cardiovascular drug development? Garber AM N Engl J Med; 2009 Mar; 360(12):1169-71. PubMed ID: 19297568 [No Abstract] [Full Text] [Related]
10. Prescription-drug prices. Frank RG N Engl J Med; 2004 Sep; 351(14):1375-7. PubMed ID: 15459294 [No Abstract] [Full Text] [Related]
11. [Discount for only one drug of the same group leads to impaired health care quality]. Bergström R Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044 [No Abstract] [Full Text] [Related]
12. Reference pricing of pharmaceuticals. Brekke KR; Königbauer I; Straume OR J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769 [TBL] [Abstract][Full Text] [Related]
13. Using a drug-safety tool to prevent competition. Sarpatwari A; Avorn J; Kesselheim AS N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666 [No Abstract] [Full Text] [Related]
14. Skies darken over drug companies. Holmes D Lancet; 2012 May; 379(9829):1863-4. PubMed ID: 22616103 [No Abstract] [Full Text] [Related]
15. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs. Hakim A; Gupta R; Ross JS JAMA; 2017 Dec; 318(22):2181-2182. PubMed ID: 29131905 [No Abstract] [Full Text] [Related]
16. We Can use Market Forces to Moderate Drug Prices. Miller HI Mo Med; 2019; 116(6):451-453. PubMed ID: 31911716 [No Abstract] [Full Text] [Related]
17. [From a crisis to another...Pharmaceutical industry--economics]. Scheen AJ Rev Med Liege; 2009 Jan; 64(1):3-5. PubMed ID: 19317093 [No Abstract] [Full Text] [Related]
19. Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative. Gunter SJ; Kesselheim AS; Rome BN JAMA Intern Med; 2021 Aug; 181(8):1124-1126. PubMed ID: 33999110 [TBL] [Abstract][Full Text] [Related]